相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
David T. Teachey et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
EEG findings in CAR T-cell therapy-related encephalopathy
Aline Herlopian et al.
NEUROLOGY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates
Agne Taraseviciute et al.
CANCER DISCOVERY (2018)
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
Aleksei Titov et al.
CELL DEATH & DISEASE (2018)
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Juliane Gust et al.
CNS DRUGS (2018)
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Chun-Meng Wang et al.
CLINICAL CANCER RESEARCH (2017)
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond
ZeNnan L. Chang et al.
TRENDS IN MOLECULAR MEDICINE (2017)
CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell-Associated Neurotoxicity
Crystal L. Mackall et al.
CANCER DISCOVERY (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Beta-trace Protein as a new noninvasive immunological Marker for Quinolinic Acid-induced impaired Blood-Brain Barrier Integrity
Andreas Baranyi et al.
SCIENTIFIC REPORTS (2017)
Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition
Sriharsha Grevich et al.
ADOLESCENT HEALTH MEDICINE AND THERAPEUTICS (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
Karen Thudium Mueller et al.
BLOOD (2017)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Survival in adults with sickle cell disease in a high-income setting
Kate Gardner et al.
BLOOD (2016)
CD19-Targeted Chimeric Antigen Receptor-Modified T-Cell Immunotherapy for B-Cell Malignancies
C. J. Turtle et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction
Hannah R. Wardill et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents
Ian A. Clark et al.
JOURNAL OF NEUROINFLAMMATION (2016)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cell signaling in NMDA preconditioning and neuroprotection in convulsions induced by quinolinic acid
Patricia Cardoso Severino et al.
LIFE SCIENCES (2011)
Quinolinic acid-induced seizures stimulate glutamate uptake into synaptic vesicles from rat brain: Effects prevented by guanine-based purines
Rejane G. Tavares et al.
NEUROCHEMICAL RESEARCH (2008)
Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes
RG Tavares et al.
NEUROCHEMISTRY INTERNATIONAL (2002)
Glutamate as a neurotransmitter in the brain: Review of physiology and pathology
BS Meldrum
JOURNAL OF NUTRITION (2000)
分享论文
